Desmopressin plus tolterodine versus desmopressin plus indomethacin for pediatric enuresis

Comparison of combination therapy with desmopressin plus tolterodine and desmopressin plus indomethacin for the treatment of pediatric enuresis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210613051564N1

Enrollment

Registered

2021-07-19

Start date

2018-03-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric enuresis. Nocturnal enuresis

Interventions

Intervention 1: Intervention group: Desmopressin plus tolterodine: A 60 mcg desmopressin tablet from Ferring Pharmaceuticals Ltd., United Kindgdom, and a 2 mg tolterodine tablet from Alhavi Pharmaceut

Eligibility

Sex/Gender

All

Age

6 Years to 17 Years

Inclusion criteria

Inclusion criteria: Age >5 years and <18 years Diagnosis of mono- or disymptomatic enuresis

Exclusion criteria

Exclusion criteria: Having previously received any treatment for enuresis Secondary causes of enuresis, including anatomic disorders of the urinary system, trauma, constipation, diabetes mellitus, diabetes insipidus, urinary tract infection, and the like.

Design outcomes

Primary

Measure	Time frame
Response to treatment in the form of the number of dry nights per month. Timepoint: 1, 3, and 5 months after the initiation of treatment. Method of measurement: By asking the children's parents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Elaheh Mousavipour

Bandar Abbas Children's Hospital

mansor110110@yahoo.com+98 76 3366 6242

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026